A cellular reporter system to evaluate endogenous fetal hemoglobin induction and screen for therapeutic compounds

• Published in: HemaSphere 2024-08, Vol.8 (8), p.e139-n/a
• Main Authors: Verheul, Thijs C. J., Gillemans, Nynke, Putzker, Kerstin, Majied, Rezin, Li, Tingyue, Vasiliou, Memnia, Eussen, Bert, Klein, Annelies, IJcken, Wilfred F. J., Akker, Emile, Lindern, Marieke, Lewis, Joe, Uhrig, Ulrike, Nakamura, Yukio, Dijk, Thamar, Philipsen, Sjaak
• Format: Article
• Language: English
• Subjects: Hematopoiesis; Red Cell and Iron Metabolism
• ISSN: 2572-9241; 2572-9241
• DOI: 10.1002/hem3.139

Reactivation of fetal hemoglobin expression alleviates the symptoms associated with β‐globinopathies, severe hereditary diseases with significant global health implications due to their high morbidity and mortality rates. The symptoms emerge following the postnatal transition from fetal‐to‐adult hemoglobin expression. Extensive research has focused on inducing the expression of the fetal γ‐globin subunit to reverse this switch and ameliorate these symptoms. Despite decades of research, only one compound, hydroxyurea, found its way to the clinic as an inducer of fetal hemoglobin. Unfortunately, its efficacy varies among patients, highlighting the need for more effective treatments. Erythroid cell lines have been instrumental in the pursuit of both pharmacological and genetic ways to reverse the postnatal hemoglobin switch. Here, we describe the first endogenously tagged fetal hemoglobin reporter cell line based on the adult erythroid progenitor cell line HUDEP2. Utilizing CRISPR‐Cas9‐mediated knock‐in, a bioluminescent tag was integrated at the HBG1 gene. Subsequent extensive characterization confirmed that the resulting reporter cell line closely mirrors the HUDEP2 characteristics and that the cells report fetal hemoglobin induction with high sensitivity and specificity. This novel reporter cell line is therefore highly suitable for evaluating genetic and pharmacologic strategies to induce fetal hemoglobin. Furthermore, it provides an assay compatible with high‐throughput drug screening, exemplified by the identification of a cluster of known fetal hemoglobin inducers in a pilot study. This new tool is made available to the research community, with the aspiration that it will accelerate the search for safer and more effective strategies to reverse the hemoglobin switch.